CDK4/6 inhibitors increase hepatotoxicity risk in patients with early and advanced breast cancer
CDK4/6 Inhibitors Linked to Liver Toxicity in Breast Cancer
This meta-analysis of 24,342 RCT participants and 400 FAERS reports indicates that CDK4/6 inhibitors are associated with significant hepatot…
New data suggests certain CDK4/6 inhibitors used to treat breast cancer may increase the risk of liver toxicity and elevated enzyme levels.
Low baseline TKa associated with longer OS of 38.5 months in endocrine-resistant MBC
Low thymidine kinase levels linked to longer survival in breast cancer
This translational analysis of a Phase III trial involving 555 patients with endocrine-resistant HR+ / HER2- metastatic breast cancer found …
A specific enzyme level called thymidine kinase may help doctors predict how well patients with certain types of breast cancer will respond …
CDK4/6 inhibitors show therapeutic potential in advanced gastrointestinal cancers, review finds
CDK4/6 inhibitors show promise against digestive cancers
This narrative review examines the role of CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) in advanced gastrointestinal cancers. It…
New review reveals how CDK4/6 drugs might work against stomach, colon, and liver cancers, but hurdles remain.
Meta-analysis of CDK4/6 inhibitor rechallenge shows improved progression-free survival in advanced breast cancer
Switching drugs offers hope for advanced breast cancer patients facing treatment failure
This meta-analysis synthesizes data from phase II and III clinical trials involving 1396 patients with hormone receptor-positive, HER2-negat…
A large review found that restarting a specific cancer drug after stopping it can delay disease growth by nearly two months compared to stan…
CDK4/6 inhibitors plus endocrine therapy improve survival in advanced hormone receptor-positive breast cancer
CDK4/6 Inhibitors Boost Survival In Advanced Breast Cancer
This meta-analysis of 11 phase 3 trials involving 6035 patients demonstrates that CDK4/6 inhibitors combined with endocrine therapy signific…
New data shows adding CDK4/6 inhibitors to hormone therapy helps patients live longer with advanced breast cancer.
CDK4/6i plus AI or fulvestrant shows similar clinical benefit in HR+ HER2- MBC
Two drugs linked to longer survival than palbociclib in breast cancer
This retrospective single-center analysis of 341 patients with HR+/HER2− MBC found that palbociclib, abemaciclib, and dalpiciclib combined w…
In a real-world analysis, two CDK4/6 inhibitors showed longer survival times than palbociclib for metastatic breast cancer patients.
FDA Approves Itovebi (Itovebi) for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
FDA approves new breast cancer drug Itovebi for a specific type of advanced cancer
The FDA approved Itovebi in combination with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, HR-positive, H…
A new oral drug, Itovebi, is now FDA-approved for advanced breast cancer with a specific genetic mutation, offering another option when horm…
Gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival versus fulvestrant monotherapy in advanced breast cancer
New Drug Combo Slashes Breast Cancer Progression Risk by 75%
This phase III randomized trial evaluated gedatolisib plus fulvestrant with or without palbociclib in patients with hormone receptor-positiv…
For patients with tough-to-treat advanced breast cancer, a new three-drug combination nearly quadrupled the time before the cancer started g…
Sequential paclitaxel-palbociclib showed no difference in ORR versus reverse sequence in ER+/HER2- breast cancer
New Test Predicts Who Needs Chemo in Breast Cancer
This randomized phase II trial evaluated sequential administration of paclitaxel and palbociclib with endocrine therapy in patients with ER+…
Doctors now have a way to spot patients who can skip chemo and go straight to safer hormone treatment.